Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

PURPOSE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line treatments for advanced EGFR-mutant non-small-cell lung cancer (NSCLC) patients. However, factors associated with outcomes after progression on first-line therapy are seldom investigated. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Cheng-Yu, Chen, Chung-Yu, Chang, Shih-Chieh, Chen, Ching-Yi, Lai, Yi-Chun, Chang, Chun-Fu, Wei, Yu-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318893/
https://www.ncbi.nlm.nih.gov/pubmed/37409246
http://dx.doi.org/10.3389/fonc.2023.1104098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318893/
https://www.ncbi.nlm.nih.gov/pubmed/37409246
http://dx.doi.org/10.3389/fonc.2023.1104098

Ejemplares similares